[go: up one dir, main page]

NO20091375L - Sekvensiell kombinasjonsterapi - Google Patents

Sekvensiell kombinasjonsterapi

Info

Publication number
NO20091375L
NO20091375L NO20091375A NO20091375A NO20091375L NO 20091375 L NO20091375 L NO 20091375L NO 20091375 A NO20091375 A NO 20091375A NO 20091375 A NO20091375 A NO 20091375A NO 20091375 L NO20091375 L NO 20091375L
Authority
NO
Norway
Prior art keywords
combination therapy
sequential combination
related disorders
angiogenesis
administering
Prior art date
Application number
NO20091375A
Other languages
English (en)
Inventor
Rakesh K Jain
Clive R Wood
Daniel T Dransfield
Antonio Arulanandam
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of NO20091375L publication Critical patent/NO20091375L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nye fremgangsmåter for behandling av angiogenese-relaterte lidelser er beskrevet. Angiogenese-relaterte lidelser behandles ved administrering av et Tie1 ektodomene-bindende middel og et VEGF-antagonist-middel.
NO20091375A 2006-10-17 2009-03-31 Sekvensiell kombinasjonsterapi NO20091375L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19
PCT/US2007/081621 WO2008048996A2 (en) 2006-10-17 2007-10-17 Sequential combination therapy

Publications (1)

Publication Number Publication Date
NO20091375L true NO20091375L (no) 2009-07-10

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091375A NO20091375L (no) 2006-10-17 2009-03-31 Sekvensiell kombinasjonsterapi

Country Status (17)

Country Link
US (1) US20080160019A1 (no)
EP (1) EP2073826A4 (no)
JP (1) JP2010506951A (no)
KR (1) KR20090067214A (no)
AU (1) AU2007311092A1 (no)
BR (1) BRPI0717760A2 (no)
CA (1) CA2666714A1 (no)
CR (1) CR10798A (no)
EA (1) EA200900562A1 (no)
EC (1) ECSP099336A (no)
IL (1) IL198026A0 (no)
MA (1) MA30901B1 (no)
MX (1) MX2009004070A (no)
NI (1) NI200900057A (no)
NO (1) NO20091375L (no)
TN (1) TN2009000136A1 (no)
WO (1) WO2008048996A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535171A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
EP2552482A2 (en) * 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887468B1 (en) * 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
CA2535171A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
AU2005272848A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
MA30901B1 (fr) 2009-11-02
JP2010506951A (ja) 2010-03-04
WO2008048996A3 (en) 2008-07-03
NI200900057A (es) 2010-02-02
WO2008048996A2 (en) 2008-04-24
WO2008048996A9 (en) 2008-09-12
KR20090067214A (ko) 2009-06-24
US20080160019A1 (en) 2008-07-03
ECSP099336A (es) 2009-06-30
EP2073826A2 (en) 2009-07-01
CA2666714A1 (en) 2008-04-24
AU2007311092A1 (en) 2008-04-24
CR10798A (es) 2009-06-09
EP2073826A4 (en) 2010-12-15
IL198026A0 (en) 2011-08-01
TN2009000136A1 (en) 2010-10-18
EA200900562A1 (ru) 2009-10-30
MX2009004070A (es) 2009-04-27
BRPI0717760A2 (pt) 2013-11-12

Similar Documents

Publication Publication Date Title
NO20091375L (no) Sekvensiell kombinasjonsterapi
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
EA200971077A1 (ru) Гетероциклические модуляторы киназы
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
CR9874A (es) Dipeptidyl peptidase inhibitors for treating diabetes
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EP1929123A4 (en) METHOD AND DEVICE ASSOCIATED TO STIMULATING TREATMENT OF DRILLING HOBS (S)
BRPI0817775A2 (pt) Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EP2303918A4 (en) METHOD FOR DOSED ADMINISTRATION OF A ACTIVIN ACTRIIA ANTAGONIST AND OBSERVATION OF TREATED PATIENTS
EP2212350A4 (en) THERAPEUTIC AND DIAGNOSTIC PROCEDURES USING TIM-3
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
MX375194B (es) Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
EP1909904A4 (en) METHOD AND APPARATUS FOR PLANTING AND ADMINISTERING RADIOTHERAPY
EP2063881A4 (en) COMPOSITION AND METHOD FOR THE EFFECTIVE AND SAFE ADMINISTRATION OF HALOPYRUVATE FOR THE TREATMENT OF CANCER
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
LT2318188T (lt) Medienos plokštės apdorojimo būdas
BRPI0906094B8 (pt) composto
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application